Christine Lovly, MD, PhD, FASCO (@christine_lovly) ranks #15 among US lung cancer KOLs on X in 2026, by engagement from fellow physicians. 25 physicians shared, quoted or replied to their posts this year. Most-discussed trials in 2026: CROWN, LIBRETTO-432. CMS Open Payments lists $108,410 in 2025 general payments.
At a Glance
- 2 posts naming a trial in 2026
- 2 trials discussed by name
- 4 colleague posts sharing slides from Christine Lovly, MD, PhD, FASCO's presentations
- Lung Cancer: US #15, Global #33 · 25 physicians engaged
- Presented at ASCO 2026, WCLC 2026 in 2026
- CMS Open Payments lists $108,410 in 2025 general payments.
This Month
What Christine Lovly, MD, PhD, FASCO has posted in the last 30 days. Updated November 10, 2026.
No trial posts in the last 30 days.
Who Amplifies Christine Lovly, MD, PhD, FASCO
Physicians who reposted Christine Lovly, MD, PhD, FASCO’s trial posts most often in 2026.
2026 Rankings
| List | US rank | Global rank | Physicians engaged | Physician engagements | |
|---|---|---|---|---|---|
| Lung Cancer | #15 | #33 | 25 | 29 | Full ranking |
From the Podium, 2025–26
Talks, posters and sessions Christine Lovly, MD, PhD, FASCO presented at SABCS 2025 and 2026 meetings, each confirmed by a public source.
- ASCO 2026 · DiscussantLIBRETTO-432 (adjuvant selpercatinib in RET fusion-positive NSCLC), plenary
- WCLC 2026 · PresentationIntervening on minimal residual disease (MRD) in lung cancer, moving beyond 'watch and wait'Source: @drshieldsmd on X ↗
What Colleagues Are Saying About Christine Lovly, MD, PhD, FASCO
2026 posts by fellow physicians that mention @christine_lovly, quoted word for word.
Here are the 5 studies we touched on during our conversation with @christine_lovly on #WCLC26 @IASLC conference highlights. ⭐️ #MAVERICK ⭐️ #ADAURA ⭐️ #HARMONi ⭐️ #PAPILLON ⭐️ #DESTINYLung04 #OncTwitter #lcsm #MedTwitter https://t.co/gSgScVThfA https://t.co/BeUvCJVXsg
First positive adjuvant pIII study wth selpercatinib in stage IB–IIIA RET-positive NSCLC: LIBRETTO-432. Impressive results!, now in #NEJM. Nicely discussed @christine_lovly TKI duration, MRD, screening, and broader biomarker testing in early-stage #ASCO26 #NSCLC #RETfusion https://t.co/AzjEl8XmqQ
HER2 #NSCL getting crowded with zongertinib, T-DXD, TDM1, sevabertinib Take- ~3% of NSCLC. 2L treatments are suboptimal. OS of ~13.5 months can be improved. @christine_lovly and colleagues at @JCOPO_ASCO https://t.co/ALDNfwyl0x
Excellent highlights from #WCLC26 with the @OncBrothers & our @cityofhope star @christine_lovly! https://t.co/WePvjvY9UF
Exquisite discussion by @christine_lovly on pioneer Libretto-432 trial focusing on the big picture: ✅ How can we screen Never Smokers to identify early-stage RET+ NSCLC? ✅How can we implement comprehensive NGS profiling to capture rare mutations? ✅How can we improve access to precious drugs for rare targets? A trial that opens the space for a more efficient public policy! @ASCO @myESMO @IASLC @lcsmchat
Excellent discussion @christine_lovly: Practice-changing EFS data, BUT key nuances remain: ~90% received adjuvant systemic therapy, OS data still immature, CNS outcomes not yet reported, and toxicity/duration questions remain (66.7% grade ≥3 TEAEs; 55% dose reductions). #ASCO26 https://t.co/nTwM4w0PHa
Christine Lovly, MD, PhD, FASCO’s Presentations
Slides from Christine Lovly, MD, PhD, FASCO’s 2026 presentations, as shared by physicians in the audience.
Exquisite discussion by @christine_lovly on pioneer Libretto-432 trial focusing on the big picture: ✅ How can we screen Never Smokers to identify early-stage RET+ NSCLC? ✅How can we implement comprehensive NGS profiling to capture rare mutations? ✅How can we improve access to https://t.co/CP6zRMlObj
Elegant discussion by @christine_lovly LIBRETTO-432 advances adjuvant #selpercatinib in RET fusion+ NSCLC, but key issues remain: chemo need, TKI duration, CNS/OS data, testing access, cost, and survivorship Precision medicine requires patients be found, tested, and supported! https://t.co/BNTbc4hfYG
Excellent discussion of LIBRETTO-432 by @christine_lovly. So many great points made. My favorite: “Precision medicine fails if patients are never tested.” All patients with NSCLC need comprehensive molecular testing, irrespective of stage. #ASCO2026 https://t.co/LNrNcRanHa
#ASCO26 Excellent discussion by @christine_lovly on #LIBRETTO432: adjuvant selpercatinib sets a new standard in resected RET+ #NSCLC. Key implications: 🔹 RET testing now essential in early-stage disease 🔹 Raises key questions on about access to care, financial toxicity, https://t.co/xQCyRo0UZB
Trials Christine Lovly, MD, PhD, FASCO Discussed in 2026
| Trial | Posts | Rank among physicians posting | Latest |
|---|---|---|---|
| CROWN | 1 | #12 of 36 | May 30, 2026 |
| LIBRETTO-432 | 1 | #37 of 53 | May 29, 2026 |
Christine Lovly, MD, PhD, FASCO on CROWN
#CROWN 7 yr data will be a highlight of #ASCO26. Transformative. But do you know the scientist behind the engineering of such an impressive molecule? Dr. Jean Cui. 👏 Shout out to Dr. Cui + many other med. chemists whose genius is foundational for making advances! @ASCO #LCSM https://t.co/pYZNsHdh7L
Christine Lovly, MD, PhD, FASCO on LIBRETTO-432
RT @UOzkerim: 🧬✨ASCO26 starts tomorrow and the lung cancer🫁 program really looks packed this year📢 From HARMONi-6 and LIBRETTO-432 to WU-…
Christine Lovly, MD, PhD, FASCO’s Most-Engaged Posts in 2026
Their own 2026 posts that fellow physicians reposted most, quoted word for word.
Median OS almost 2 years in ES-SCLC with Tarlatamab+Durvalumab maintenance = practice changing! ➡️ Challenge remains implementing Tarlatamab broadly + equitably so that all patients with ES-SCLC may benefit from this revolutionary therapy. @OncoAlert #ESMO26 @NEJM https://t.co/Ug6TxnAd1J
“#CancerResearch saves lives” When the great Alice Shaw talks, we all listen! #AACR26 @AACR_CEO @AACRPres @DanaFarber @AACRFoundation https://t.co/XWPmICTGO7
#AACR26 Fellows dinner celebrating the groundbreakers in #cancerresearch. Congrats to all the new members of the society! @AACR @AACRFoundation @AACR_CEO @AACRPres https://t.co/udqMv3s6PS
Joy at every session at #AACR26! This is my fave photo so far! Love seeing @AACRPres Lillian Siu laughing + enjoying the meeting with colleagues. @AACR https://t.co/CccWtLkAs4
Impressive data on #nextgen #KRAS G12C inhibitor, Elisrasib, at #AACR26. ORR 73.5% with durable responses to >= 3y in treatment naive population! #LCSM @yonsei_u https://t.co/lEyYChUsru
Industry Payments
CMS Open Payments · 2025 general payments
$108,410 across 54 payments